We are at the forefront of life sciences technology, working in close partnership with our customers to create a better world. We develop cutting-edge fluid control and detection solutions which empower Life Science OEMs to accelerate drug discovery and therapeutic research, diagnose disease earlier, and provide patient-focused critical care.
In fluid control, our precise, accurate and robust solutions improve efficiency and productivity, and also reduce waste and downtime for OEMs across many industries.
Market trends and our response
Advancements in personalised medicine, continued focus on improving preventative diagnostics, and an increasingly ageing population are some of the major underlying factors driving the Life Science market. Through our relationship with customers, we are attuned to how these trends impact the way in which patients are being diagnosed and treated. The need for extremely high-quality research, diagnostic, and medical instrumentation continues to grow, which underpins long-term market growth.
In 2024, we faced another challenging year, reflecting continued softness in the global Life Science instrumentation market. De-stocking, geopolitical uncertainty, and a slow-down in China all contributed to reduced end-customer demand and lower R&D spending at the OEM level. Encouragingly, we are seeing Life Science companies beginning to reinitiate R&D programmes delayed in prior years.
Our structure allows us to be nimble and flexible, supporting both large OEMs with their existing technology platforms and smaller players that are developing breakthrough solutions. By understanding the requirements of our customers, we are developing innovations to support next-generation platform developments. Our fluidics and detection expertise reduces the customer’s engineering burden of managing the ‘sample-to-answer’ workflow, allowing them to focus their efforts on critical diagnostic science improvements.
Our customers also want local, trusted experts who can support their manufacturing and design challenges. With our global manufacturing and engineering footprint, we deliver real value through our engineers and scientists interfacing with our customers’ technology teams across the world.
Revenue
IMI growth target
Creating value in Life Sciences
We empower our customers to digitise and automate their processes to diagnose disease early and support highly tailored, patient-focused critical care.
2024 highlights
– Continued expansion of our Active Controls range of products, working with OEMs to develop new prototypes for use in nextgeneration instruments
– Continued customer roll-out of our Air Infinity pipettor – our lightweight, self-contained pipetting system with a wide dispense range; through customer feedback we are developing next-generation products focused on ease-of-use and pipetting flexibility
– Successful market-led innovation to develop and supply differentiated valves and control solutions in aseptic and energy efficient PET blowing systems
Priorities for 2025 and beyond
We have used the current market softness to stabilise our business post the COVID-19 era, and are preparing the organisation for longterm, sustainable growth. Our priorities in 2025 are to firstly continue collaborating with customers and building our project pipeline. As our customers’ R&D programmes come back online, we are in an excellent position to create customer value utilising our Growth Hub methodology.
Secondly, we continue to selectively invest in our technology portfolio. Finally, we are investing in our people. Engineers, scientists, and application experts who continue to be a critical differentiator for Life Science. We are continuing to develop our teams to ensure we have the right skillsets and depth to solve our customers’ most complex challenges.